Braveheart Bio Inc.

08/05/2026 | Press release | Distributed by Public on 08/05/2026 19:14

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Forbion Growth Opportunities Fund III Cooperatief U.A.
2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2026
3. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [BRVE]
(Last) (First) (Middle)
GOOIMEER 2-35
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
NAARDEN 1411 DC
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 588,126 D(1)
Common Stock 514,611 I By Forbion Ventures Fund VII Cooperatief U.A.(2)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (3) (3) Common Stock 9,132,420 (3) D(1)
Series A Preferred Stock (3) (3) Common Stock 7,990,867 (3) I By Forbion Ventures Fund VII Cooperatief U.A.(2)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Forbion Growth Opportunities Fund III Cooperatief U.A.
GOOIMEER 2-35
NAARDEN 1411 DC
X
Forbion Growth III Management B.V.
GOOIMEER 2-35
NAARDEN 1411 DC
X
Forbion Ventures Fund VII Cooperatief U.A.
GOOIMEER 2-35
NAARDEN 1411 DC
X
Forbion Ventures VII Management B.V.
GOOIMEER 2-35
NAARDEN 1411 DC
X

Signatures

Forbion Growth Opportunities Fund III Cooperatief U.A., By: /s/ M.A. van Osch and /s/ G.J. Mulder, Directors of Director of Director 08/05/2026
**Signature of Reporting Person Date
Forbion Growth III Management B.V., By: /s/ M.A. van Osch and /s/ G.J. Mulder, Directors of Director 08/05/2026
**Signature of Reporting Person Date
Forbion Ventures Fund VII Cooperatief U.A., By: /s/ M.A. van Osch and /s/ G.J. Mulder, Directors of Director of Director 08/05/2026
**Signature of Reporting Person Date
Forbion Ventures VII Management B.V., By: /s/ M.A. van Osch and /s/ G.J. Mulder, Directors of Director 08/05/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
(2) Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
(3) Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis at the option of the holder, and will convert automatically immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Braveheart Bio Inc. published this content on August 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 06, 2026 at 01:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]